메뉴 건너뛰기




Volumn 21, Issue 2, 2013, Pages 136-141

Systemic and brain bioavailabilities of D-Phenylglycine-L-Dopa, a sustained dopamine-releasing prodrug

Author keywords

Anti Parkinsonism activity; Brain homogenate; CNS bioavailability; D Phenylglycine L Dopa; PepT1

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PHENYLGLYCINE; PHENYLGLYCINE LEVO DOPA; PRODRUG; UNCLASSIFIED DRUG;

EID: 84881418423     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfda.2013.05.001     Document Type: Article
Times cited : (5)

References (23)
  • 1
    • 65449135642 scopus 로고    scopus 로고
    • Levodopa: Past, present, and future
    • Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1-8.
    • (2009) Eur Neurol , vol.62 , pp. 1-8
    • Hauser, R.A.1
  • 2
    • 65449189759 scopus 로고    scopus 로고
    • Optimizing levodopa therapy
    • Abbruzzese G. Optimizing levodopa therapy. Neurol Sci 2008;29:S377-9.
    • (2008) Neurol Sci , vol.29
    • Abbruzzese, G.1
  • 3
    • 57349093766 scopus 로고    scopus 로고
    • Levodopa for the treatment of Parkinson's disease
    • LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-76.
    • (2008) N Engl J Med , vol.359 , pp. 2468-2476
    • LeWitt, P.A.1
  • 4
    • 66949117423 scopus 로고    scopus 로고
    • The scientific and clinical basis for the treatment of Parkinson disease
    • Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(Suppl. 4):S1-136.
    • (2009) Neurology , vol.72 , Issue.SUPPL. 4
    • Olanow, C.W.1    Stern, M.B.2    Sethi, K.3
  • 5
    • 58149120928 scopus 로고    scopus 로고
    • L-Dopa therapy for Parkinson's disease: Past, present, and future
    • Nagatsu T, Sawada M. L-Dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 2009;15(Suppl. 1):S3-8.
    • (2009) Parkinsonism Relat Disord , vol.15 , Issue.SUPPL. 1
    • Nagatsu, T.1    Sawada, M.2
  • 6
    • 58149141585 scopus 로고    scopus 로고
    • Levodopa therapeutics for Parkinson's disease: New developments
    • LeWitt PA. Levodopa therapeutics for Parkinson's disease: new developments. Parkinsonism Relat Disord 2009;15(Suppl. 1):S31-4.
    • (2009) Parkinsonism Relat Disord , vol.15 , Issue.SUPPL. 1
    • LeWitt, P.A.1
  • 7
    • 0026526135 scopus 로고
    • Levodopa: Pharmacology, pharmacokinetics, and pharmacodynamics
    • Juncos JL. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics. Neurol Clin 1992;10:487-509.
    • (1992) Neurol Clin , vol.10 , pp. 487-509
    • Juncos, J.L.1
  • 8
    • 58149180322 scopus 로고    scopus 로고
    • Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease
    • Nomoto M, Nishikawa N, Nagai M, et al. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl. 1):S21-4.
    • (2009) Parkinsonism Relat Disord , vol.15 , Issue.SUPPL. 1
    • Nomoto, M.1    Nishikawa, N.2    Nagai, M.3
  • 9
    • 0028262953 scopus 로고
    • Dietary factors in the management of Parkinson's disease
    • Kempster PA, Wahlqvist ML. Dietary factors in the management of Parkinson's disease. Nutr Rev 1994;52:51-8. (Pubitemid 24090161)
    • (1994) Nutrition Reviews , vol.52 , Issue.2 I , pp. 51-58
    • Kempster, P.A.1    Wahlqvist, M.L.2
  • 11
    • 34948908635 scopus 로고    scopus 로고
    • The pharmacokinetics and pharmacodynamics of Levodopa in the treatment of Parkinson's disease
    • DOI 10.2174/157488407781668802
    • Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007;2:234-43. (Pubitemid 47520962)
    • (2007) Current Clinical Pharmacology , vol.2 , Issue.3 , pp. 234-243
    • Khor, S.-P.1    Hsu, A.2
  • 12
    • 0025869874 scopus 로고
    • Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease
    • Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-9.
    • (1991) Ann Neurol , vol.29 , pp. 556-559
    • Olanow, C.W.1    Gauger, L.L.2    Cedarbaum, J.M.3
  • 13
    • 50049087567 scopus 로고    scopus 로고
    • Molecular mechanisms of L-dopa-induced dyskinesia
    • Jenner P. Molecular mechanisms of L-dopa-induced dyskinesia. Nat Rev Neurosci 2008;9:665-77.
    • (2008) Nat Rev Neurosci , vol.9 , pp. 665-677
    • Jenner, P.1
  • 14
    • 0037407662 scopus 로고    scopus 로고
    • L-DOPA, dyskinesia and striatal plasticity
    • DOI 10.1038/nn0503-437
    • Dunnett S. L-dopa, dyskinesia and striatal plasticity. Nat Neurosci 2003;6:437-8. (Pubitemid 36514685)
    • (2003) Nature Neuroscience , vol.6 , Issue.5 , pp. 437-438
    • Dunnett, S.1
  • 16
    • 78049400764 scopus 로고    scopus 로고
    • Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption
    • Wang CL, Fan Y, Lu HH, et aL Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. J Biomed Sci 2010;17:71.
    • (2010) J Biomed Sci , vol.17 , pp. 71
    • Wang, C.L.1    Fan, Y.2    Lu, H.H.3
  • 18
    • 0027449341 scopus 로고
    • Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats
    • DOI 10.1016/0006-8993(93)90576-9
    • Hudson JL, van Home CG, Stromberg I, et al. Correlation of apomorphine and amphetamine induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993;626:167-74. (Pubitemid 23306825)
    • (1993) Brain Research , vol.626 , Issue.1-2 , pp. 167-174
    • Hudson, J.L.1    Van Horne, C.G.2    Stromberg, I.3    Brock, S.4    Clayton, J.5    Masserano, J.6    Hoffer, B.J.7    Gerhardt, G.A.8
  • 19
    • 19444370500 scopus 로고    scopus 로고
    • Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
    • DOI 10.1016/j.bbr.2005.02.023, PII S0166432805000707
    • Iancu R, Mohapel P, Brundin P, et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005;162:1-10. (Pubitemid 40726275)
    • (2005) Behavioural Brain Research , vol.162 , Issue.1 , pp. 1-10
    • Iancu, R.1    Mohapel, P.2    Brundin, P.3    Paul, G.4
  • 20
    • 0035344211 scopus 로고    scopus 로고
    • Experimental models of Parkinson's disease
    • Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001;2:325-34.
    • (2001) Nat Rev Neurosci , vol.2 , pp. 325-334
    • Beal, M.F.1
  • 21
    • 34548819330 scopus 로고    scopus 로고
    • The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease
    • DOI 10.1016/j.parkreldis.2007.06.005, PII S1353802007001071
    • Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl. 1):S13-7. (Pubitemid 47444538)
    • (2007) Parkinsonism and Related Disorders , vol.13 , Issue.SUPPL. SEPT.
    • Nyholm, D.1
  • 22
    • 33746105694 scopus 로고    scopus 로고
    • Continuous dopamine-receptor treatment of Parkinson's disease: Scientific rationale and clinical implications
    • DOI 10.1016/S1474-4422(06)70521-X, PII S147444220670521X
    • Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006,5:677-87. (Pubitemid 44081890)
    • (2006) Lancet Neurology , vol.5 , Issue.8 , pp. 677-687
    • Olanow, C.W.1    Obeso, J.A.2    Stocchi, F.3
  • 23
    • 69749091694 scopus 로고    scopus 로고
    • Levodopa delivery systems for the treatment of Parkinson's disease: An overview
    • Goole J, Amighi K. Levodopa delivery systems for the treatment of Parkinson's disease: an overview. Int J Pharm 2009;380:1-15.
    • (2009) Int J Pharm , vol.380 , pp. 1-15
    • Goole, J.1    Amighi, K.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.